Werewolf TherapeuticsHOWL
HOWL
About: Werewolf Therapeutics Inc is a biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer. It is leveraging its proprietary PREDATOR platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. Its INDUKINE molecules are intended to remain inactive in peripheral tissue yet activate selectively in the tumor microenvironment or TME.
Employees: 45
0
Funds holding %
of 6,809 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
92% more repeat investments, than reductions
Existing positions increased: 25 | Existing positions reduced: 13
0% more funds holding in top 10
Funds holding in top 10: 2 [Q2] → 2 (+0) [Q3]
0% more call options, than puts
Call options by funds: $1K | Put options by funds: $1K
1.14% less ownership
Funds ownership: 74.29% [Q2] → 73.15% (-1.14%) [Q3]
3% less funds holding
Funds holding: 70 [Q2] → 68 (-2) [Q3]
13% less first-time investments, than exits
New positions opened: 13 | Existing positions closed: 15
14% less capital invested
Capital invested by funds: $78.8M [Q2] → $67.8M (-$11M) [Q3]
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
Low target
$15
874%
upside
Avg. target
$15
874%
upside
High target
$15
874%
upside
1 analyst rating
1 positive
100%
0 neutral
0%
0 negative
0%
HC Wainwright & Co. Andres Maldonado 28% 1-year accuracy 13 / 46 met price target | 874%upside $15 | Buy Reiterated | 19 Nov 2024 |
Financial journalist opinion
Neutral
GlobeNewsWire
1 month ago
Werewolf Therapeutics to Participate in the 7th Annual Evercore ISI HealthCONx Healthcare Conference
WATERTOWN, Mass., Nov. 20, 2024 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body's immune system for the treatment of cancer and other immune-mediated conditions, today announced that Daniel J. Hicklin, Ph.D., President and Chief Executive Officer of Werewolf, and Randi Isaacs, M.D., Chief Medical Officer of Werewolf, will participate in a fireside chat at 12:55 pm ET on Thursday, December 5, 2024, at the 7th Annual Evercore ISI HealthCONx Healthcare Conference, taking place December 3-5 in Miami, Florida.
Neutral
GlobeNewsWire
1 month ago
Werewolf Therapeutics Presents Preclinical and Clinical Data at the Society for Immunotherapy of Cancer's (SITC) 39th Annual Meeting
- Interim phase 1 clinical trial update reveals the clinical potential of the tumor-activated IL-12 prodrug WTX-330, with favorable tolerability profile and encouraging efficacy signals -
Neutral
GlobeNewsWire
2 months ago
Werewolf Therapeutics to Present Posters at the Society for Immunotherapy of Cancer's (SITC) 39th Annual Meeting
WATERTOWN, Mass., Oct. 04, 2024 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body's immune system for the treatment of cancer, today announced that two posters will be presented at the upcoming Society for Immunotherapy of Cancer's (SITC) 39th Annual Meeting, taking place November 6-10, 2024, in Houston, Texas.
Negative
Zacks Investment Research
4 months ago
Werewolf Therapeutics, Inc. (HOWL) Reports Q2 Loss, Lags Revenue Estimates
Werewolf Therapeutics, Inc. (HOWL) came out with a quarterly loss of $0.43 per share versus the Zacks Consensus Estimate of a loss of $0.38. This compares to loss of $0.14 per share a year ago.
Neutral
GlobeNewsWire
4 months ago
Werewolf Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update
– Positive data from ongoing Phase 1/1b clinical trial of WTX-124 presented at American Society of Clinical Oncology (ASCO) Annual Meeting –
Positive
Seeking Alpha
5 months ago
Werewolf Therapeutics: Continuing To Advance And Show More Promise In Phase 1
Werewolf Therapeutics, Inc. is an early-stage biotech focusing on cytokine therapy for cancer treatment. The Pipeline update includes positive results for WTX-124 in clinical trials and promising data for WTX-330. Financially, the company has a decent cash position for now, but may need to address cash burn rate in the near future.
Neutral
GlobeNewsWire
6 months ago
Werewolf Therapeutics Highlights Initial Safety and Efficacy Data from its Ongoing Phase 1 Clinical Trial Evaluating WTX-330 in Patients with Advanced or Metastatic Solid Tumors or Non-Hodgkin Lymphoma
- Data demonstrate that administration of WTX-330 reached therapeutically relevant exposure levels of systemically delivered IL-12 prodrug with an improved tolerability profile over historical data for rhIL-12 -
Neutral
GlobeNewsWire
6 months ago
Werewolf Therapeutics to Present Data from Ongoing Phase 1/1b Clinical Trial of WTX-124 as Monotherapy and in Combination with Pembrolizumab in Solid Tumors
- WTX-124 was shown to be clinically active and generally well-tolerated in patients who were relapsed/refractory to immune checkpoint inhibitor therapy -
Neutral
GlobeNewsWire
6 months ago
Werewolf Therapeutics to Participate at the Jefferies Global Healthcare Conference
WATERTOWN, Mass., May 30, 2024 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body's immune system for the treatment of cancer, today announced that Daniel J. Hicklin, Ph.D., President and Chief Executive Officer of Werewolf, and Randi Isaacs, M.D., Chief Medical Officer of Werewolf, will participate in a fireside chat at 1:00 PM ET on June 6 at the Jefferies Global Healthcare Conference, taking place June 4-6, 2024, in New York City, New York.
Neutral
GlobeNewsWire
7 months ago
Werewolf Therapeutics to Present Updated Data from Phase 1/1b Clinical Trial of WTX-124 as Monotherapy and in Combination with Pembrolizumab in Solid Tumors at 2024 ASCO Annual Meeting
- Updated single agent dose escalation data continues to demonstrate that WTX-124 is well tolerated and clinically active in patients with checkpoint inhibitor therapy relapsed/refractory cancers -
Charts implemented using Lightweight Charts™